Contineum Therapeutics Inc
NASDAQ:CTNM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
People's Insurance Company Group of China Ltd
SSE:601319
|
CN |
During the last 3 months Contineum Therapeutics Inc insiders have not bought any shares, and sold 502.2k USD worth of shares. The stock price has increased by 14% over this period (open performance analysis).
The last transaction was made on Apr 6, 2026 by Lorrain Daniel S. , who sold 56k USD worth of CTNM shares.
During the last 3 months Contineum Therapeutics Inc insiders have not bought any shares, and sold 502.2k USD worth of shares. The stock price has increased by 14% over this period (open performance analysis).
The last transaction was made on Apr 6, 2026 by Lorrain Daniel S. , who sold 56k USD worth of CTNM shares.
Contineum Therapeutics Inc
Glance View
Contineum Therapeutics Inc is a US-based company operating in industry. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2024-04-05. Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The firm is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).
What is Insider Trading?
Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
